SARS-CoV-2 (COVID-19) Antibody, IgG, Qualitative
CPT Code(s):
86413
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Serum
Minimum Volume:
1.0 mL
Transport Container:
Serum Separator Tube (SST) or Red Top Tube
Transport Temperature:
Room Temperature
Collection Instructions:
Allow blood to clot completely prior to centrifugation. Separate serum from cells within 45 minutes of collection.
Rejection Criteria:
Sodium Citrate plasma; gross hemolysis; lipemia; improper labeling
Stability Criteria
Room Temperature:
8 hours
Refrigerated:
48 hours
Frozen:
30 days
Clinical Significance
The SARS-CoV-2 (COVID-19) IgG IA Qn is a clinical used to measure the quantity of IgG antibodies specific to the SARS-CoV-2 virus in a patient's blood. This test utilizes an immunoassay technique to provide quantitative results, indicating the level of IgG antibodies present in the patient's system.
The clinical significance and diagnostic use of the SARS-CoV-2 IgG IA Qn include:
1. Past Infection Confirmation: The presence of IgG antibodies specific to SARS-CoV-2 indicates that the patient has been previously infected with the virus and has mounted an immune response. This test can be used to confirm a past COVID-19 infection, especially in individuals who were not tested during the acute phase of the illness or those who were asymptomatic.
2. Immune Response Evaluation: The quantitative nature of the test allows for the assessment of the patient's immune response to the SARS-CoV-2 virus. Higher IgG antibody levels generally indicate a stronger and more robust immune response. This information can help healthcare professionals evaluate the patient's immune status and potentially inform decisions regarding immunity and potential protection against reinfection.
3. Vaccine Response Monitoring: The SARS-CoV-2 IgG IA Qn can be used to assess the immune response following COVID-19 vaccination. By measuring the level of IgG antibodies post-vaccination, the test can provide insights into the individual's vaccine-induced immune response and help evaluate the effectiveness of the vaccination.
4. Epidemiological Studies: The test is valuable in population-level studies to estimate the prevalence of SARS-CoV-2 infections, monitor the spread of the virus within communities, and evaluate the effectiveness of public health measures and vaccination campaigns.
It is important to note that the SARS-CoV-2 IgG IA Qn should not be used as a standalone diagnostic tool for acute COVID-19 infection. Molecular tests such as PCR are recommended for the diagnosis of active infection. Additionally, the interpretation of antibody test results should consider the timing of the test, the patient's symptoms, and other clinical factors.
In summary, the SARS-CoV-2 IgG IA Qn is a valuable tool for confirming past COVID-19 infection, evaluating the immune response, monitoring vaccine efficacy, and contributing to epidemiological studies. It provides quantitative information about the level of IgG antibodies against SARS-CoV-2 in the patient's blood, aiding in the understanding and management of the COVID-19 pandemic.
CPT Code(s):
86413
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Serum
Minimum Volume:
1.0 mL
Transport Container:
Serum Separator Tube (SST) or Red Top Tube
Transport Temperature:
Room Temperature
Collection Instructions:
Allow blood to clot completely prior to centrifugation. Separate serum from cells within 45 minutes of collection.
Rejection Criteria:
Sodium Citrate plasma; gross hemolysis; lipemia; improper labeling
Stability Criteria
Room Temperature:
8 hours
Refrigerated:
48 hours
Frozen:
30 days
Clinical Significance
The SARS-CoV-2 (COVID-19) IgG IA Qn is a clinical used to measure the quantity of IgG antibodies specific to the SARS-CoV-2 virus in a patient's blood. This test utilizes an immunoassay technique to provide quantitative results, indicating the level of IgG antibodies present in the patient's system.
The clinical significance and diagnostic use of the SARS-CoV-2 IgG IA Qn include:
1. Past Infection Confirmation: The presence of IgG antibodies specific to SARS-CoV-2 indicates that the patient has been previously infected with the virus and has mounted an immune response. This test can be used to confirm a past COVID-19 infection, especially in individuals who were not tested during the acute phase of the illness or those who were asymptomatic.
2. Immune Response Evaluation: The quantitative nature of the test allows for the assessment of the patient's immune response to the SARS-CoV-2 virus. Higher IgG antibody levels generally indicate a stronger and more robust immune response. This information can help healthcare professionals evaluate the patient's immune status and potentially inform decisions regarding immunity and potential protection against reinfection.
3. Vaccine Response Monitoring: The SARS-CoV-2 IgG IA Qn can be used to assess the immune response following COVID-19 vaccination. By measuring the level of IgG antibodies post-vaccination, the test can provide insights into the individual's vaccine-induced immune response and help evaluate the effectiveness of the vaccination.
4. Epidemiological Studies: The test is valuable in population-level studies to estimate the prevalence of SARS-CoV-2 infections, monitor the spread of the virus within communities, and evaluate the effectiveness of public health measures and vaccination campaigns.
It is important to note that the SARS-CoV-2 IgG IA Qn should not be used as a standalone diagnostic tool for acute COVID-19 infection. Molecular tests such as PCR are recommended for the diagnosis of active infection. Additionally, the interpretation of antibody test results should consider the timing of the test, the patient's symptoms, and other clinical factors.
In summary, the SARS-CoV-2 IgG IA Qn is a valuable tool for confirming past COVID-19 infection, evaluating the immune response, monitoring vaccine efficacy, and contributing to epidemiological studies. It provides quantitative information about the level of IgG antibodies against SARS-CoV-2 in the patient's blood, aiding in the understanding and management of the COVID-19 pandemic.
CPT Code(s):
86413
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Serum
Minimum Volume:
1.0 mL
Transport Container:
Serum Separator Tube (SST) or Red Top Tube
Transport Temperature:
Room Temperature
Collection Instructions:
Allow blood to clot completely prior to centrifugation. Separate serum from cells within 45 minutes of collection.
Rejection Criteria:
Sodium Citrate plasma; gross hemolysis; lipemia; improper labeling
Stability Criteria
Room Temperature:
8 hours
Refrigerated:
48 hours
Frozen:
30 days
Clinical Significance
The SARS-CoV-2 (COVID-19) IgG IA Qn is a clinical used to measure the quantity of IgG antibodies specific to the SARS-CoV-2 virus in a patient's blood. This test utilizes an immunoassay technique to provide quantitative results, indicating the level of IgG antibodies present in the patient's system.
The clinical significance and diagnostic use of the SARS-CoV-2 IgG IA Qn include:
1. Past Infection Confirmation: The presence of IgG antibodies specific to SARS-CoV-2 indicates that the patient has been previously infected with the virus and has mounted an immune response. This test can be used to confirm a past COVID-19 infection, especially in individuals who were not tested during the acute phase of the illness or those who were asymptomatic.
2. Immune Response Evaluation: The quantitative nature of the test allows for the assessment of the patient's immune response to the SARS-CoV-2 virus. Higher IgG antibody levels generally indicate a stronger and more robust immune response. This information can help healthcare professionals evaluate the patient's immune status and potentially inform decisions regarding immunity and potential protection against reinfection.
3. Vaccine Response Monitoring: The SARS-CoV-2 IgG IA Qn can be used to assess the immune response following COVID-19 vaccination. By measuring the level of IgG antibodies post-vaccination, the test can provide insights into the individual's vaccine-induced immune response and help evaluate the effectiveness of the vaccination.
4. Epidemiological Studies: The test is valuable in population-level studies to estimate the prevalence of SARS-CoV-2 infections, monitor the spread of the virus within communities, and evaluate the effectiveness of public health measures and vaccination campaigns.
It is important to note that the SARS-CoV-2 IgG IA Qn should not be used as a standalone diagnostic tool for acute COVID-19 infection. Molecular tests such as PCR are recommended for the diagnosis of active infection. Additionally, the interpretation of antibody test results should consider the timing of the test, the patient's symptoms, and other clinical factors.
In summary, the SARS-CoV-2 IgG IA Qn is a valuable tool for confirming past COVID-19 infection, evaluating the immune response, monitoring vaccine efficacy, and contributing to epidemiological studies. It provides quantitative information about the level of IgG antibodies against SARS-CoV-2 in the patient's blood, aiding in the understanding and management of the COVID-19 pandemic.